Alzheon is set to present Phase 3 trial data for ALZ-801 in April 2025, a drug designed to prevent the formation of toxic beta-amyloid plaques in early Alzheimer's patients with the ApoE4 gene.
The global Alzheimer's disease market is projected to grow at a CAGR of 23.4%, expanding from $2.4B in 2023 to $19.3B by 2033 across eight major markets.
Alzheon's ALZ-801 demonstrated a 29% reduction in plasma p-tau181 levels at 26 weeks in patients with early Alzheimer's, indicating a potential disease-modifying effect.